Royal Bank of Canada
TSHA icon

Royal Bank of Canada’s Taysha Gene Therapies TSHA Stock Holding History

Royal Bank of Canada’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
191
-6,111
-97% -$28.4K ﹤0.01% 6964
2025
Q4 		$34K Sell
6,302
-577,073
-99% -$2.8M ﹤0.01% 5766
2025
Q3 		$1.91M Buy
583,375
+88,064
+18% +$249K ﹤0.01% 3448
2025
Q2 		$1.15M Buy
495,311
+493,849
+33,779% +$1.07M ﹤0.01% 3779
2025
Q1 		$2K Sell
1,462
-5,073
-78% -$8.49K ﹤0.01% 6598
2024
Q4 		$11K Sell
6,535
-29,805
-82% -$61.8K ﹤0.01% 6330
2024
Q3 		$72K Buy
36,340
+20,644
+132% +$45.3K ﹤0.01% 5530
2024
Q2 		$35K Buy
+15,696
New +$45.7K ﹤0.01% 5827
2023
Q4 		– Sell
-19
Closed – – 7594
2023
Q3 		$0 Sell
19
-131
-87% -$245 ﹤0.01% 7607
2023
Q2 		$0 Buy
150
+128
+582% +$93 ﹤0.01% 7675
2023
Q1 		$0 Sell
22
-2
-8% -$3 ﹤0.01% 7486
2022
Q4 		$0 Buy
24
+5
+26% +$10 ﹤0.01% 7730
2022
Q3 		$0 Sell
19
-1,000
-98% -$3.63K ﹤0.01% 7872
2022
Q2 		$4K Sell
1,019
-1,392
-58% -$5.52K ﹤0.01% 6763
2022
Q1 		$16K Sell
2,411
-2,204
-48% -$16.5K ﹤0.01% 6728
2021
Q4 		$53K Buy
4,615
+2,598
+129% +$39.2K ﹤0.01% 6346
2021
Q3 		$38K Buy
2,017
+485
+32% +$9.22K ﹤0.01% 6326
2021
Q2 		$32K Buy
1,532
+657
+75% +$15.1K ﹤0.01% 6309
2021
Q1 		$18K Buy
875
+406
+87% +$11K ﹤0.01% 6488
2020
Q4 		$12K Buy
+469
New +$10.1K ﹤0.01% 6305

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's TSHA Position: Q1 2026 in Review

Royal Bank of Canada reduced its Taysha Gene Therapies (TSHA) stake by 97% in Q1 2026, selling an estimated $28.4K and leaving 191 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6964.

Royal Bank of Canada first reported a position in TSHA in Q4 2020 and has held it in 20 quarters since. The position peaked at $1.91M in Q3 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Royal Bank of Canada held 191 shares of Taysha Gene Therapies worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 6,111 Taysha Gene Therapies shares in Q1 2026, an estimated $28.4K.
  • Taysha Gene Therapies made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6964 holding.
  • Royal Bank of Canada first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 20 quarters since.
  • Royal Bank of Canada's Taysha Gene Therapies position peaked at $1.91M in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.